Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

Exclusion Criteria

• •1. Patients treated with chemo-immunotherapy associations
• •2. Patients treated with immunotherapy combinations (e.g. subjects treated with anti-CTLA4 + anti-PD1/PDL1 are excluded)
• •3. Patients receiving immunotherapy within clinical trials
• •4. Patients receiving off-label immunotherapy or within expanded access programs or as compassionate use
• •5. Patients with high tumor burden defined as \> 10 lesions and/or sum of diameters \> 19 cm
• •6. Patients with distant metastases only located in the CNS are excluded
• •7. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results
• •8. Patients with autoimmune diseases (ADs), including local and systemic collagen-vascular (CVD) and inflammatory bowel diseases (IBD)
• •9. Previous RT, regardless of energy, on the metastatic site selected to be irradiated.
• •10. Any immune-related CTCAE grade 4 adverse event, before study entry
• •11. Any CTCAE grade ≥3 immune-related adverse event observed within 3 weeks prior to CIRT start
• •12. Presence of metal prostheses or any other condition to prevent adequate imaging for identification of the target volume and calculation of the dose
• •13. Loco-regional conditions not allowing hadron therapy (e.g. active infections in RT target region)
• •14. Prisoners or subjects who are involuntarily incarcerated
• •15. Subjects who are compulsorily detained for treatment of either a psychiatric or physical illness (e.g. infectious disease)